{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9"},{"groupId":"OG001","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Monitoring of efficacy results will be performed in comparison with historical results.","groups":[{"description":"All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride \\& intrathecal triple therapy (ITT: methotrexate, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (methotrexate, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide \\& ITT.","id":"OG000","title":"CNS Patients - Treatment (Combination Chemotherapy)"},{"description":"All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride \\& intrathecal triple therapy (ITT: methotrexate, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (methotrexate, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide \\& ITT.","id":"OG001","title":"Testicular Relapse Patients (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"The CNS-treatment cohort includes 126 patients with 120 CNS pre-B, 2 CNS+ITR pre-B and 4 T-AL. The primary analysis was restricted to CNS pre-B and ITR pre-B patients, respectively. Both CNS+ITR and T-ALL patients had to be excluded from the primary analysis. That is how we came to 120 in the CNS-treatment cohort for outcome analysis.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}